Amyris Stock Forecast, Price & News

Amyris (NASDAQ:AMRS) Frequently Asked Questions

Is Amyris a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amyris stock.
View analyst ratings for Amyris or view top-rated stocks.

How has Amyris' stock been impacted by COVID-19 (Coronavirus)?

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMRS shares have increased by 125.7% and is now trading at $6.68.
View which stocks have been most impacted by COVID-19.

Are investors shorting Amyris?

Amyris saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 31,020,000 shares, an increase of 44.1% from the October 31st total of 21,520,000 shares. Based on an average daily trading volume, of 4,660,000 shares, the short-interest ratio is currently 6.7 days. Currently, 17.8% of the company's stock are short sold.
View Amyris' Short Interest.

When is Amyris' next earnings date?

Amyris is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Amyris.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) issued its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $47.90 million for the quarter, compared to analyst estimates of $64.21 million. The firm's revenue for the quarter was up 39.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.41) EPS.
View Amyris' earnings history.

When did Amyris' stock split? How did Amyris' stock split work?

Shares of Amyris reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

What guidance has Amyris issued on next quarter's earnings?

Amyris issued an update on its FY 2021 earnings guidance on Monday, November, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $330 million-$370 million.

What price target have analysts set for AMRS?

5 brokers have issued 12 month price targets for Amyris' stock. Their forecasts range from $15.00 to $30.00. On average, they expect Amyris' share price to reach $22.00 in the next year. This suggests a possible upside of 229.3% from the stock's current price.
View analysts' price targets for Amyris or view top-rated stocks among Wall Street analysts.

Who are Amyris' key executives?

Amyris' management team includes the following people:

• John G. Melo, President, Chief Executive Officer & Director (LinkedIn Profile)
• Eduardo Alvarez, Chief Operating Officer (LinkedIn Profile)
• Han Kieftenbeld, Chief Financial & Administration Officer
• Sunil Chandran, Senior Vice President-Research & Development
• Charles Kraft, SVP-Global Manufacturing & Process Development

What is John Melo's approval rating as Amyris' CEO?

53 employees have rated Amyris CEO John Melo on Glassdoor.com. John Melo has an approval rating of 54% among Amyris' employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amyris' key competitors?

Some companies that are related to Amyris include Marathon Petroleum (MPC), Phillips 66 (PSX), Valero Energy (VLO), HollyFrontier (HFC), Renewable Energy Group (REGI), Green Plains (GPRE), World Fuel Services (INT), Clean Energy Fuels (CLNE), CVR Energy (CVI), PBF Energy (PBF), Gevo (GEVO), Delek US (DK), REX American Resources (REX) and Adams Resources & Energy (AE).
View all of AMRS's competitors.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.06%), Farallon Capital Management LLC (3.80%), Pinnacle Associates Ltd. (1.56%), Geode Capital Management LLC (1.12%), Lord Abbett & CO. LLC (1.09%) and Carmignac Gestion (0.49%). Company insiders that own Amyris stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, John Melo, L John Doerr, Nicole Kelsey and Patrick Y Yang.
View institutional ownership trends for Amyris.

Which major investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Invesco Ltd., Goldman Sachs Group Inc., Renaissance Technologies LLC, Ghisallo Capital Management LLC, Davy Global Fund Management Ltd, Cubist Systematic Strategies LLC, and Jump Financial LLC. Company insiders that have sold Amyris company stock in the last year include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, John Melo, and Nicole Kelsey.
View insider buying and selling activity for Amyris or view top insider-selling stocks.

Which major investors are buying Amyris stock?

AMRS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., State of Michigan Retirement System, Edmond DE Rothschild Holding S.A., Nordea Investment Management AB, Connor Clark & Lunn Investment Management Ltd., Vident Investment Advisory LLC, Vantis Investment Advisers L.P., and Pura Vida Investments LLC. Company insiders that have bought Amyris stock in the last two years include Frank Kung, and L John Doerr.
View insider buying and selling activity for Amyris or or view top insider-buying stocks.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $6.68.

How much money does Amyris make?

Amyris has a market capitalization of $2.06 billion and generates $173.14 million in revenue each year. The biotechnology company earns $-331.04 million in net income (profit) each year or ($1.95) on an earnings per share basis.

How many employees does Amyris have?

Amyris employs 595 workers across the globe.

When was Amyris founded?

Amyris was founded in 2003.

What is Amyris' official website?

The official website for Amyris is amyris.com.

Where are Amyris' headquarters?

Amyris is headquartered at 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at (510) 450-0761, via email at [email protected], or via fax at 510-225-2645.